Contract Pharma2h
FDA Approves Fapon Biopharma’s FP008 Cancer Therapy IND Application
The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
EVA Films Market worth $11.26 billion by 2029 - Exclusive Report by MarketsandMarkets™
Anti-PID EVA is anticipated to be the second largest segment in EVA Films Market segment, by type, during the forecast period. Anti-PID EVA films represent the second largest market share in the EVA ...
FDA accepts Sobi’s Gamifant application for HLH/MAS treatment
The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that ...
Hosted on MSN21h
Regeneron makes second bid for blood cancer therapy approval
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...